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ABSTRACT
Acute myeloid leukaemia (AML) cells often up-regulate pro-survival members of the 
BCL-2 protein family, such as BCL-2 and MCL-1, to avoid apoptosis. Venetoclax (ABT-199) 
targets BCL-2 and has shown promising efficacy in AML but over-expression of MCL-1 
can cause resistance. A co-operative approach, targeting both BCL-2 and MCL-1 may 
therefore prove beneficial. This study investigated the potential synergistic relationship 
between Venetoclax and the MCL-1 inhibitor S63845 in AML cells. We treated MV4-11 
cells and primary AML samples for 4 hours with Venetoclax, S63845 or the combination. 
We used a short-term flow cytometric technique to assess synergy using cytochrome C 
release as a read out of response. The combination of Venetoclax and S63845 produced 
a synergistic apoptotic response in MV4-11 cells and primary samples, including the 
leukaemia re-populating leukaemic stem cell (LSC) population, in 92% of the samples. 
Known molecular biomarkers of response to BCL-2 and MCL-1 targeting agents were 
corroborated, and augmented, with the short-term functional assay. The assay also 
predicted potential biomarkers of response to the combination of BCL-2 and MCL-1 
targeting agents. Primary samples with an IDH2_140 mutation were more sensitive to 
Venetoclax as a single agent whereas samples with a FLT3-ITD mutation were more 
resistant. This resistance could be reversed when combined with S63845. All FLT3-ITD 
and NPM1 mutated samples were sensitive to the combination of drugs.
We report that co-operatively targeting BCL-2 and MCL-1 may be beneficial in 
AML and a short-term in vitro assay can identify patients who might best respond to 
this combination.
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INTRODUCTION
AML is a malignant clonal disorder of the 
progenitor cells in the bone marrow. The heterogeneity 
of the disease and of patient related factors makes 
prognosis and predicting responses to treatment difficult. 
Despite a substantial increase in the understanding of the 
pathophysiology, cytogenetics and molecular genetics 
of AML, treatment options have advanced only slowly 
over the past 40 years [1]. In 2017 however, four drugs 
received US Food and Drug Administration (FDA) 
approval for treating AML. These include midostaurin and 
enasidenib targeting mutant FLT3 and IDH2 respectively, 
the liposomal cytarabine-daunorubicin formulation CPX-
351, and the re-approval of the CD33 targeting antibody 
gemtuzumab ozogomycin [2]. The emergence of BH3-
mimetics designed to target the anti-apoptotic members 
of the BCL-2 (B-cell lymphoma-2) family has provided 
another exciting therapeutic option. The apoptotic fate of a 
cell depends on a fine balance of interactions between pro-
survival molecules such as BCL-2, MCL-1 (Myeloid Cell 
Leukaemia-1) and BCL-XL (B cell lymphoma-extra-large) 
and BH3-only protein sensitizer molecules such as BAD 
(BCL-2 associated death promotor) and NOXA (PMAIP1; 
Phorbol-12myristate-13-acetate-induced protein 1) [3]. 
Following a cell death stimulus, BH3-only sensitizer 
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proteins are activated, and displace BH3-only activator 
proteins such as BIM (BCL-2 interacting mediator of cell 
death) and BID (BH3 interacting-domain death agonist) 
from their pro-survival molecular chaperones, resulting in 
activation of effector molecules BAX (BCL-2 associated X 
protein) and BAK (BCL-2 homologous antagonist killer). 
BAX and BAK subsequently oligomerise and form pores 
that cause mitochondrial outer membrane permeabilisation 
resulting in cytochrome C release and apoptosis. 
Overexpression of BCL-2 is associated with tumour 
progression and resistance to chemotherapy in multiple 
malignancies, including AML [4, 5]. The most promising 
BCL-2 inhibitor to date is the BH3 mimetic Venetoclax, 
which has demonstrated clinical promise in AML, 
particularly when used in combination with cytarabine 
or hypomethylating agents [6, 7]. Dormant LSCs can 
repopulate a leukaemia following treatment, resulting in 
relapse, and a defining characteristic of these cells is high 
levels of BCL-2 [8]. We have previously demonstrated 
that these leukaemia re-populating cells are sensitive to 
Venetoclax treatment [9]. MCL-1 is also a crucial pro-
survival factor in AML [10]. We have previously reported 
that a number of agents that indirectly inhibit MCL-1 
expression produce a synergistic apoptotic response when 
used in combination with Venetoclax in AML cells [11, 12]. 
Resistance to Venetoclax monotherapy is associated with 
released BIM being sequestered by MCL-1 and others have 
reported that this can be reversed by combining Venetoclax 
with cytarabine or daunorubicin [13]. Until now a truly 
selective and potent small molecule inhibitor of MCL-1 has 
not been developed and a worrying caveat is that genetic 
deletion of MCL-1 in mouse models resulted in bone 
marrow failure and myocardial toxicity [14]. It is hoped 
that transient inhibition of MCL-1 using a BH3-mimetic 
drug could circumvent these side effects. S63845 is a novel 
MCL-1 targeting BH3-mimetic, developed by Servier, that 
has shown low toxicity in pre-clinical models and has 
demonstrated syergy in combination with Venetoclax in 
T-cell acute lymphoblastic leukaemia [15–17].
Predictive assays to demonstrate which drugs an 
individual patient will best respond to are still lacking. 
An issue that limits traditional chemosensitivity assays 
is that AML cells are fragile ex vivo, and most will die 
spontaneously in culture fairly rapidly [18, 19]. By 
focusing on a same-day functional assay, with intact cells, 
we aim to overcome this obstacle. Using this assay, we 
demonstrate that co-operative targeting of BCL-2 and 
MCL-1 with the BH3-mimetics Venetoclax and S63845 
induces an enhanced apoptotic response in bulk and LSC 
populations of primary AML samples. Known molecular 
biomarkers of response to single agents were corroborated 
using the assay. The assay also augmented our knowledge 
of current biomarkers along with predicting potential 
biomarkers of response to the combination of BCL-2 and 
MCL-1 targeting agents.
RESULTS
Co-operative dynamic BH3 profiling
Dynamic BH3 profiling is a technique that 
involves priming mitochondria following short-term 
drug exposure and measuring subsequent BH3 peptide-
induced cytochrome C release [20]. Using the technique 
we have previously shown that the BCL-2 antagonist 
Venetoclax sensitises to the MCL-1 inhibitory MS1-
BH3 peptide, whilst agents that target MCL-1 non-
specifically, sensitise to the BCL-2 inhibitory BAD-
BH3 peptide [11]. However, despite exhibiting synergy 
with Venetoclax, the specific MCL-1 binding inhibitor 
A-1210477 failed to prime to BAD-BH3 at sub-
micromolar concentrations. It was therefore important to 
test the credentials of S63845 as a BH3-mimetic in this 
system. We used MV4-11 cells in this assay as they are 
sensitive to BCL-2 and MCL-1 targeting agents but they 
do not over-express BCL-XL [12]. We used the synthetic 
peptide MS1 as it binds to MCL-1 with higher affinity 
than NOXA-BH3 [21]. Venetoclax was included as an 
experimental control and priming to MS1-BH3 peptide 
was confirmed (Figure 1). S63845 primed to BAD-
BH3 peptide but not to MS1-BH3 peptide confirming 
its credentials as a BH3-mimetic and suggesting its co-
operative potential with Venetoclax. The concentrations 
of Venetoclax and S63845 used in the experiment were 
determined as previously reported [11].
Co-operative induction of apoptosis with the 
combination of Venetoclax and S63845 in  
MV4-11 cells
MV4-11 cells were treated for four hours with 
Venetoclax and S63845 alone or in combination followed 
by measurement of cytochrome C release (Figure 2A). The 
FLT3 inhibitor AC220 was included as an experimental 
control as we have previously demonstrated its co-
operative induction of apoptosis in MV4-11 cells in 
combination with Venetoclax [11]. Dose response assays 
were performed to select the drug concentration that 
produced 0-20% cytochrome C release as a single agent. 
A strong synergistic apoptotic response was observed 
with the combination of Venetoclax and S63845 at low 
nanomolar concentrations. We have previously reported 
apoptotic synergy with Venetoclax using various drugs that 
target MCL-1 non-specifically. All of these non-specific 
agents caused MCL-1 protein degradation as single 
agents after four hours [11]. Here we show that there is 
no reduction of MCL-1 protein expression when S63845 
is used as a single agent (Figure 2B). The combination 
of S63845 and Venetoclax results in loss of MCL-1 
protein whilst BCL-2 expression remains unchanged. See 
Supplementary Figure 1 for uncropped blots.
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Co-operative induction of apoptosis with the 
combination of Venetoclax and S63845 in 
primary AML samples 
Primary AML samples were treated for four 
hours with Venetoclax, S63845 and AC220 alone, or in 
combination followed by measurement of cytochrome C 
release (Figure 3). Experience with the assay has taught 
us that using 10x the drug concentration used in cell 
lines should give us the range of cytochrome C release 
with single agents that allows us to detect any synergy in 
primary samples. The FLT3 inhibitor AC220 was included 
as an experimental control as when used as a single 
agent we would expect it to specifically target samples 
bearing a high FLT3-ITD mutant allelic burden [22]. This 
would indicate whether this assay was a good predictor 
of primary samples response to drugs. Interestingly the 
combination of AC220 and S63845 resulted in >60% 
Figure 1: Co-operative dynamic BH3 profiling assay: delta priming to BAD-BH3 and MS1-BH3 peptides. Delta priming 
in MV4-11 cells is measured by cytochrome C release after 4 hours Venetoclax (50 nM) S63845 (5 nM) drug treatment and additional 
incubation with the indicated BH3 peptides (BAD-BH3 at 3 µM, MS1-BH3 at 3 µM, PUMA2A control at 100 µM). Values are corrected 
for cytochrome C release with peptide only as described in the methods. Columns, mean of three experiments; bars, SD (n = 3).
Figure 2: Co-operative induction of apoptosis with the combination of Venetoclax and S63845. (A) MV4-11 cells were 
treated with 10 nM Venetoclax, 10 nM AC220, 2.5 nM or 5 nM S63845 or the indicated combinations. After 4 hours, cells were fixed and 
processed for cytochrome C release. Columns, mean of three experiments; bars, SD (n = 3). Asterisks indicate synergy according to the 
Bliss Independence model as described in the methods. (B) MCL-1 and BCL-2 protein was quantified in untreated MV4-11 cells (Lane 1) 
or cells treated for four hours with 10 nM Venetoclax (Lane 2), 5 nM S63845 (Lane 3) or the drug combination (Lane 4). The blots shown 
are cropped and an example of two independent experiments.
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synergistic response in primary sample bulk and LSC 
populations. By far the most striking synergy resulted 
from the combination of Venetoclax and S63845 with 20 
out 21 (95%) samples (Bulk population) and 12 out of 13 
(92%) samples (LSC population) showing synergy using 
the higher dose of S63845. In the only sample, (AML-20) 
where synergy was not seen in the LSC population, this 
was due to a maximal response to Venetoclax as a single 
agent. Figure 4A (Bulk cells) and 4B (LSC) show raw 
data for primary samples treated with the combination 
that gave the best response as shown in Figure 3 (100 nM 
Venetoclax or 50 nM S63845 alone or a combination of 
both) along with statistical analysis (Figure 4C and 4D).
A short-term cytochrome C release assay 
predicts primary sample response to drugs
Assays that predict what drug an individual AML 
patient will best respond to are still lacking. An issue 
is that primary AML cells often survive poorly in vitro, 
thus confounding conventional cytotoxicity assays 
[19]. We have previously demonstrated two short-term 
flow cytometric assays that predict long term chemo-
responsiveness to drugs in AML cell lines [23]. We 
investigated whether a four hour cytochrome C release 
assay could confirm drug response to known molecular 
biomarkers and predict other markers of response. Having 
a FLT3-ITD mutation does not necessarily predict response 
to FLT3 inhibitors, particularly in vitro. The  FLT3-ITD 
allelic burden appears a better predictor of response 
[22]. Our data corroborates this in that the amount of 
cytochrome C release after four hours of AC220 treatment 
correlated with the FLT3-ITD  allelic burden (p = 0.041) 
indicating the assay could be a useful predictor of drug 
response (Figure 5). The most striking correlation resulting 
from our data was the impact of isocitrate dehydrogenase 
(IDH) mutational status on the sensitivity to Venetoclax 
as a single agent (p = 0.003) (Figure 6A). This agrees 
with early clinical data that has indicated that patients 
with an IDH1/2 mutation could preferentially benefit 
from Venetoclax therapy [24, 25]. Our data suggetsts that 
patients with an IDH2_140 mutation might specifically 
benefit. The more common IDH2_140 mutated samples 
were the most responsive to Venetoclax when compared to 
wild-type samples (p = 0.0004) (Figure 6B). One possibly 
unexpected result was the synergy seen in primary samples 
with the combination of the FLT3 inhibitor AC220 and 
the MCL-1 targeting S63845 (Figure 3). Mutation of 
FLT3 results in up-regulation of the pro-survival protein 
MCL-1 through STAT5 activation [26]. This combination 
of drugs is therefore targeting MCL-1 through two 
separate mechanisms and the FLT3-ITD primary samples 
Figure 3: Co-operative induction of apoptosis with the combination of Venetoclax and S63845 in primary AML 
samples–Summary of drug combination response. Primary AML cells were treated with single agent or the indicated combinations 
of Venetoclax (100 nM), AC220 (100 nM) and S63845 (25 nM or 50 nM). After 4 hours, cells were fixed and processed for cytochrome C 
release. The LSC (leukaemic stem cell) population was distinguished from the bulk population by CD34/CD38 staining. The darker part 
of the bar demonstrates the percentage of primary samples exhibiting synergy for a particular drug combination. Synergy was calculated 
according to the Bliss Independence model as described in the methods.
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(p = 0.048) (Figure 7) responded best to this combination. 
All FLT3-ITD and NPM1 mutated samples were 
sensitive to cytochrome C release when treated with 
the combination of Venetoclax and S63845 (p = 0.015) 
(Figure 8). Also of note was that the FLT3-ITD samples 
were relatively resistant to single agent Venetoclax when 
compared to wild-type samples (p = 0.014) (Figure 9A). 
Conversely, FLT3-ITD samples were more sensitive to 
S63845 as a single agent (p = 0.027) (Figure 9B). FLT3-
ITD sample resistance to Venetoclax could be reversed 
when combined with S63845 (Figure 9C).
DISCUSSION
Our inability to target the leukaemia re-populating 
LSCs with conventional chemotherapy is a confounding 
issue in the progress of AML therapy. A major finding in 
recent years has been the identification of high levels of 
BCL-2 as a defining characteristic of LSCs [8]. Venetoclax 
is a clinically established BCL-2 targeting BH3-mimetic 
that has FDA approval for use in CLL patients with a 17p 
deletion [27, 28]. In November 2018, Venetoclax gained 
FDA approval for use in combination with low-dose 
cytarabine or hypomethylating agents, in the treatment 
of AML. A phase II Venetoclax monotherapy study in 
older patients who had many high-risk features resulted 
in a promising 19% complete morphologic response 
[24]. However, despite their initial response, all patients 
treated with Venetoclax eventually relapsed, suggesting 
a resistance mechanism to Venetoclax monotherapy. This 
prompted clinical trials using Venetoclax in combination 
with other drugs in AML and impressive clinical responses, 
particularly when used in combination with cytarabine or 
hypomethylating agents, have already been documented 
[7, 29]. Resistance to Venetoclax monotherapy is 
associated with pro-apoptotic BIM, being released from 
BCL-2, which is then sequestered by over-expressed 
MCL-1 or BCL-XL anti-apoptotic proteins [30]. MCL-1 
Figure 4: Co-operative induction of apoptosis with the combination of Venetoclax and S63845 in primary AML 
samples. Primary AML cells were treated with 100 nM Venetoclax or 50 nM S63845 or a combination of both. After 4 hours, cells were 
fixed and processed for cytochrome C release. Cytochrome C release is shown in the bulk population of cells (A) (n = 21) and the LSC 
population of cells (B) (n = 13). Asterisks indicates synergy according to the Bliss Independence model as described in the methods. 
Summarising the median interquartile range (boxes) and range (error bars) of cytochrome C release in the bulk population of 21 primary 
AML samples (C) and the LSC population of 13 samples (D).
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is the preferred target, as agents such as Navitoclax that 
target both BCL-2 and BCL-XL, have resulted in platelet 
toxicity and dose limiting thrombocytopenia [31]. When 
used in combination with Venetoclax, cytarabine results 
in decreased MCL-1 protein levels, decreased association 
of MCL-1 with BIM, and synergistic induction of cell 
death in AML cells [13]. By simultaneously targeting 
MCL-1, resistance to Venetoclax may be avoided, and 
we and other groups have reported that dual targeting of 
BCL-2 and MCL-1 in AML produces an enhanced cell 
killing response [11, 32–34]. Worryingly though, it has 
been reported that simultaneous inhibition of BCL-2 
and MCL-1, synergistically inhibits the proliferation of 
peripheral blood mononuclear cells as well as AML cells 
[32]. In addition, deletion of MCL-1 in mouse models 
resulted in bone marrow failure and myocardial toxicity 
[14]. It is hoped that these problems can be avoided by 
transiently targeting MCL-1 with a BH3-mimetic and 
importantly simultaneous targeting of BCL-2 and MCL-1 
with BH3-mimetics resulted in minimal toxicity to normal 
haematopoietic progenitor cells [33]. S63845 is a novel 
MCL-1 targeting BH3-mimetic that has demonstrated low 
toxicity in pre-clinical models and kills AML cells as a 
single agent [15]. We previously reported that although the 
specific MCL-1 binding inhibitor A-1210477 produced a 
supra-additive effect in combination with Venetoclax in 
AML cells, it failed to prime to BAD-BH3 peptide in a 
BH3 profiling assay [11]. We confirmed here using BH3 
profiling that S63845 does prime to BAD-BH3 peptide 
and is thus acting at the mitochondria as a bona fide 
BH3-mimetic. We have also previously reported drugs 
that indirectly target MCL-1, when used in combination 
with Venetoclax, produce a synergistic apoptotic response 
[11, 12]. All of these MCL-1 targeting drugs resulted in 
MCL-1 protein depletion as single agents. We confirm 
here that S63845 does not result in loss of MCL-1 
protein as a single agent suggesting its different and 
potentially clinically beneficial mechanism of action. The 
combination of S63845 and Venetoclax resulted in MCL-1 
depletion whilst BCL-2 expression remained unchanged. 
This difference is likely reflected by the very short half-
life of MCL-1 (approximately one hour) when compared 
to BCL-2 (10–14 hours) [35, 36].
Here we also report a same day functional assay, 
using primary AML samples, which demonstrates the co-
operative potential of targeting both BCL-2 and MCL-1, 
along with identifying molecular biomarkers of response. 
This assay could offer clinicians a faster and more targeted 
therapeutic window when compared to mouse PDX 
models and colony assays. The short time frame of the 
assay is important as AML cells are particularly fragile in 
vitro, and the majority will die spontaneously in culture 
fairly rapidly [19]. We saw a significant co-operative 
response using the combination of Venetoclax and S63845 
in MV4-11 cells and primary samples. The synergistic 
response seen in primary samples was remarkable, 
particularly considering the short time frame of the assay, 
and was much greater than we have previously reported 
with agents that target MCL-1 indirectly [12]. Importantly, 
this response was also seen in the leukaemia re-populating 
LSC populations of primary samples. LSCs are the most 
difficult cell subgroup to therapeutically target in AML and 
are usually the source of resistance and relapse [37]. The 
dual targeting of BCL-2 and MCL-1 therefore offers the 
Figure 5: Apoptotic response to AC220 in primary AML samples correlates to FLT3 ITD allelic burden. Primary AML 
cells were treated with 100 nM AC220 for 4 hours. Cells were then fixed and processed for cytochrome C release.
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exciting potential of achieving deeper levels of sustainable 
remission in AML patients. 
Along with being a short-term readout of response, 
the cytochrome C release assay was able to confirm known 
molecular markers of response to single agents, and 
predict biomarkers to the drug combination. The assays 
validity of being a useful predictor of drug response was 
demonstrated, as the amount of cytochrome C release 
following treatment with the FLT3 inhibitor AC220, 
correlated with the amount of FLT3-ITD mutant allelic 
Figure 6: IDH mutational status in primary AML samples predicts apoptotic response to Venetoclax. Primary AML cells 
were treated with 100 nM Venetoclax for 4 hours. Cells were then fixed and processed for cytochrome C release. Samples are grouped 
as either wild-type or mutant according to IDH2_140 (filled diamonds), IDH1_132 (closed diamonds) or IDH2_172 (square) mutational 
status (A) or IDH2_140 mutational status (B).
Figure 7: FLT3 mutational status in primary AML samples predicts apoptotic response to MCL-1 targeting agents. 
Primary AML cells were treated with the combination of 50 nM S63845 and 100 nM AC220 for 4 hours. Cells were then fixed and 
processed for cytochrome C release and grouped as either wild-type or mutant according to FLT3 mutational status.
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burden in the primary samples [22]. The assay was further 
validated with the sensitivity of IDH mutated samples to 
Venetoclax as a single agent. IDH mutations are known 
to induce BCL-2 dependence and early clinical data has 
indicated that patients with an IDH1/2 mutation could 
preferentially benefit from Venetoclax therapy [24, 25, 38]. 
Here we report for the first time that patients with the 
more common IDH2_140 mutation might specifically 
benefit. The samples we tested with the less common 
IDH1_132 or IDH2_172 mutations were less sensitive to 
Venetoclax than those with an IDH2_140 mutation were. 
All three IDH mutations result in elevated levels of the 
oncometabolite 2-hydroxyglutarate (2-HG), although the 
mutations are not functionally equivalent, and a better 
prognosis for patients with IDH2_140 mutations versus 
those with IDH1_132 or IDH2_172 mutations has been 
reported by multiple groups [39–41]. 2-HG accumulation 
leads to inhibition of cytochrome C oxidase and disruption 
of the mitochondrial electron transport chain, lowering the 
apoptotic threshold of cells, making them dependent on 
BCL-2 for survival [38]. An IDH2_172 mutation leads 
to greater accumulation of 2-HG than does an IDH2_140 
mutation suggesting a less severe phenotype in the 
IDH2_140 mutated cells and potentially explaining the 
differences in sensitivities to Venetoclax [42].
There was only one primary sample LSC population 
where no drug synergy was observed with the combination 
of Venetoclax and S63845 and this was because the 
sample was particularly sensitive to Venetoclax as a 
single agent. Unsurprisingly, this sample had an IDH_140 
Figure 8: FLT3 and NPM1 mutated primary AML samples are sensitive to the combination of Venetoclax and S63845. 
Primary AML samples were treated with a combination of 100 nM Venetoclax and 50 nM S63845 for 4 hours. Cells were then fixed and 
processed for cytochrome C release. Samples are grouped as FLT3-/NPM1- (filled diamonds), FLT3+/NPM1- (open diamonds), FLT3-/
NPM1+ (filled squares) or FLT3+/NPM1+ (open squares).
Figure 9: Apoptotic resistance to Venetoclax in FLT3 mutated primary samples can be reversed when combined with 
S63845. Primary AML cells were treated with 100 nM Venetoclax (A), 50 nM S63845 (B) or a combination of both (C) for 4 hours. Cells 
were then fixed and processed for cytochrome C release. Samples are grouped as either wild-type or mutant according to FLT3 mutational 
status.
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mutation, and on further investigation, it was also found to 
harbour a DNMT3A mutation. DNMT3A mutations have 
been associated with activated RAS kinase signalling and 
subsequent overexpression of BCL-2 [43, 44]. Further 
research is required to examine if patients with this 
combination of mutations might preferentially benefit 
from Venetoclax treatment.
FLT3-ITD primary samples were more sensitive to 
S63845 as a single agent and this might be expected as 
mutation of the FLT3 receptor results in up-regulation 
of MCL-1 through STAT5 activation [26]. Conversely, 
FLT3 mutated samples were less sensitive to Venetoclax, 
but this was reversed with the addition of S63845. 
Notably, all primary samples that had a FLT3 or NPM1 
mutation were sensitive to the combination of Venetoclax 
and S63845. FLT3 mutated primary samples were also 
particularly sensitive to the combination of S63845 
and the FLT3 inhibitor AC220. MCL-1 is up regulated 
in FLT3 mutated cells through STAT5 activation [26]. 
This suggests that FLT3-ITD samples can be sensitised 
by targeting MCL-1 through two separate mechanisms. 
Other groups have reported TP53 mutated samples to 
be sensitive to Venetoclax whilst others report the drugs 
mechanism of action to be independent of TP53 status [6, 
45]. All of our primary samples were TP53 wild-type so 
we cannot add to this debate. Importantly, the molecular 
markers of response identified using the cytochrome C 
release assay, correlate with early clinical findings using 
Venetoclax. A phase 1/2 study that combined Venetoclax 
with low-dose cytarabine reported NPM1, FLT3-ITD, 
DNMT3A and IDH1/2 mutations as possible biomarkers 
of response [25].
In conclusion, co-operative targeting of BCL-2 and 
MCL-1 results in synergistic apoptosis in primary AML 
cells including the LSC population. We report a real-
time cytochrome C release assay which confirms known 
biomarkers of response to drugs and identifies others. 
The assay has the potential to determine which patient 
sub-groups are likely to respond to novel agents in the 
future. The assay could be particularly useful in predicting 
response to agents that directly target anti-apoptotic BCL-
2 proteins, such as BH3-mimetics.
MATERIALS AND METHODS
Reagents
Drugs and reagent suppliers used in the study 
were as follows: Venetoclax (ABT-199) was supplied 
by Bioquote limited, York, UK, and S63845 (Active 
Biochem, Kowloon, Hong Kong), AC220 (Stratech 
Scientific Ltd, Ely, UK). BIM, BAD, MS1 and PUMA2A 
BH3 peptides were supplied by Genscript (Piscataway, NJ, 
USA). All other reagents were from Sigma (Poole, Dorset, 
UK) unless specified.
Primary samples
The investigation was conducted on samples obtained 
with informed consent in accordance with the ethical 
standards and according to the Declaration of Helsinki and 
according to national and international guidelines and has 
been approved by the authors’ institutional review board. 
Mononuclear cells were obtained by standard methods 
from bone marrow or peripheral blood samples of patients 
with AML and cells were cryopreserved until use. Only 
samples with >90% post-thaw viability were assayed. 
FLT3 and NPM mutations were determined as reported 
previously [46]. The majority of p53 mutations occur in 
exons 5–9 and therefore only these exons were assessed. 
Screening for p53 and IDH1/2 and mutations was via high 
resolution melting curve analysis with MeltDoctor HRM 
mastermix (Thermo Fisher Scientific, Loughborough UK) 
and performed on a 7500 Fast Real Time PCR system 
(Thermo Fisher Scientific) according to the manufacturer’s 
instructions. Supplementary Table 1 contains the primer 
sequences. All mutated and 10% of samples assigned 
wild-type by HRM were verified by sequencing. All 
primary samples tested were p53 wild-type. Patient sample 
demographics are listed in Table 1.
Cells
MV4-11 cells were obtained from the American 
Type Culture Collection (Manassas, VA, USA) and 
maintained in RPMI 1640 medium with 10% foetal 
calf serum (FCS; First Link, Birmingham, UK), 
2 mM L-glutamine, 100 U/ml penicillin and 10µg/ml 
streptomycin. Cultures were sustained at 37°C in 5% 
CO2 and all experiments were performed with cell lines 
in log phase. Regular testing to authenticate these cells 
was performed using multiplex short tandem repeat 
analysis (Powerplex 16, Promega, Southampton, UK). 
Mycoplasma testing was routinely performed using the 
Mycoalert mycoplasma detection kit (Lonza, Rockland, 
USA) and following the manufacturer’s instructions.
Dynamic BH3 profiling
MV4-11 cells were incubated at 5 × 105/ml in 
culture medium for four hours with the indicated drug. 
Cytochrome c release (using Alexa-647-conjugated 
cytochrome c antibody, Becton Dickinson) was measured 
after a further 60 minute incubation of digitonin 
permeabilised cells with BH3 peptides as described [12, 
47]. Adjustments for peptide-induced cytochrome c release 
in untreated cells were made in order to establish agent-
specific release (delta priming), using the formula 100X 
(percent cytochrome c positive with peptide – percent 
cytochrome c positive with drug plus peptide)/(percent 
cytochrome c positive with peptide). A mutated PUMA-
BH3 peptide (PUMA2A) (Ryan et al. 2013) at 100 µM 
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and BIM-BH3 peptide (10 µM) were used as controls in all 
experiments. Data were collected on a FACSCanto II flow 
cytometer (Becton Dickinson) and analysed with FACS 
Diva software (Becton Dickinson).
Cytochrome C release assay
MV4-11 cells were incubated at 5 × 105/ml in culture 
medium for four hours with Venetoclax (10 nM), AC220 
(10 nM) or S63845 (2.5 nM/5 nM) or a combination of 
drugs. Primary AML samples were incubated at 1 × 106/ml 
in culture medium for four hours with Venetoclax 
(100 nM), AC220 (100 nM) or S63845 (25 nM/50 nM) 
or a combination of drugs. To measure the percentage of 
cells with loss of cytochrome C, cells were fixed in 2% 
para-formaldehyde following 4-hour drug incubation. 
Fixed and rinsed cells were permeabilised with saponin 
and labelled with Alexa-647-conjugated cytochrome C 
antibody. Leukaemic blast cells were identified using 
CD45 APC-H7 antibody (Becton Dickinson). LSCs were 
identified using CD34 PerCP antibody (Becton Dickinson) 
and CD38 (AT1) PE antibody (Beckton Dickinson). Data 
were collected on a FACSCanto II flow cytometer (Becton 
Dickinson) and analysed with FACS Diva software 
(Becton Dickinson).
Western blot analysis
MV4-11 cells were treated for four hours with 10 
nM Venetoclax, 5 nM S63845 or the drug combination. 
Cell lysates were prepared, separated by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis, 
and transferred to nitrocellulose membranes. Detection 
antibodies included anti-MCL1 (S-19, sc-819) and anti-
Bcl-2 (C-2) from Santa Cruz Biotechnology, Santa Cruz, 
CA, USA and anti-β-actin from Abcam, Cambridge, UK.
Table 1: Characteristics of primary AML patient samples
Sample ID Gender Age (years) Disease Status Genetic mutations(s) % FLT3-ITD
AML-1 Male 38 Newly diagnosed NPM1, FLT3-ITD 32
AML-2 Female 64 Newly diagnosed NPM1, FLT3-ITD, IDH2_140 30
AML-3 Male 71 Newly diagnosed NPM1 -
AML-4 Male 73 Newly diagnosed - -
AML-5 Female 51 Newly diagnosed NPM1, FLT3-ITD 42
AML-6 Male 57 Newly diagnosed FLT3-ITD 91
AML-7 Male 76 Newly diagnosed - -
AML-8 Male 20 Newly diagnosed FLT3-ITD 46
AML-9 Female 70 Newly diagnosed FLT3-ITD 42
AML-10 Male 37 Newly diagnosed NPM1, IDH2_140 -
AML-11 Female 51 Newly diagnosed IDH2_172 -
AML-12 Female 48 Newly diagnosed IDH1_132 -
AML-13 Male 70 Newly diagnosed IDH2_140 -
AML-14 Male 79 Newly diagnosed NPM1, FLT3-ITD, IDH1_132 45
AML-15 Female 83 Newly diagnosed NPM1, FLT3-ITD 43
AML-16 Male 78 Newly diagnosed NPM1, IDH2_140 -
AML-17 Female 35 Newly diagnosed NPM1 -
AML-18 Male 68 Newly diagnosed IDH2_140 -
AML-19 Male 41 Newly diagnosed FLT3-ITD, IDH2_140 32.6
AML-20 Female 65 Newly diagnosed IDH2_140, DNMT3aǂ -
AML-21 Female 60 Newly diagnosed FLT3-ITD 21.4
AML-22 Male 78 Relapsed IDH1_132 -
AML-23 Male 68 Newly diagnosed IDH2_140 -
AML-24 Female 66 Newly diagnosed - -
AML-25 Male 76 Newly diagnosed NPM1, FLT3-ITD 42
AML-26 Male 67 Newly diagnosed NPM1, FLT3-ITD, IDH2_140 41
ǂThis was the only sample sequenced for a DNMT3a mutation.
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Calculations and statistics
Fold excess additivism was calculated as a ratio of 
observed to expected values for drug combinations, where 
the expected value C is calculated from the Bliss algorithm 
for response to two compounds with effects A and B i.e. 
C= A + B –A*B [48]. This method allows for potentiation 
and augmentation as well as synergism. Statistical analysis 
was performed using the Statistical Package for Social 
Sciences, version 23 (SPSS, Chicago, IL, USA). P values 
of ≤0.05 were considered to represent significance.
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